netFormulary NHS
Isle of Wight
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Chemotherapy drugs are frequently given in combination.

Disease specific protocols are approved at local and network level.

Only approved protocols should be used. All chemotherapy treatment decisions should be made by a consultant grade oncologist or haematologist, with input from the relevant multidisciplinary team. 

 Chemotherapy drugs, including oral therapies must be prescribed, dispensed and administered only by suitably trained staff. 

Paediatric cancer therapies are initiated and prescribed from tertiary cancer centres. The exception is maintenance treatment for some cancers, which is prescribed by designated paediatricians only.

Cancer Drugs Fund (CDF) - Drug List

Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Atezolizumab
(Tecentriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
Ceritinib (Zykadia) Black Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Ibrutinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Pablociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Pembrolizumab
(Keytruda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA357: Pembrolizumab for melanoma after ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA531 : Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Trifluridine-tipiracil
(Lonsurf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
(Oncology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: 1st line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin
(Adcetris®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
08.01.05  Expand sub section  Cetuximab to top
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Yellow
CCG

 CCG commissioned:

Sickle Cell Anaemia - Siklos

 

 
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

NHSE Commissioned:

Essential thrombocythaemia, myelofibrosis or polycythaemia with high risk of complications. 

 

As these indications are commissioned by NHSE they should not be prescribed in primary care

 
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Platinum compounds to top
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Erlotinib (Tarceva®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Cytotoxic Drug Imatinib Black Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Only Glivec brand is part of the black triangle scheme

 
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cytotoxic Drug Docetaxel (Taxotere®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Topotecan (Hycamtin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Drugs that may be initiated, stabilised and maintained by primary, secondary or tertiary care Secondary and tertiary care prescribing may be continued by primary care. [this does not indicate first/second line choice]  

Green Hospital

Items used by the Hospital but would not normally be continued into primary care. Primary care prescribers can change to GREEN first or second.   

Green plus

Initiation of drugs by primary care following written advice from secondary/ tertiary care advice.  

Yellow

Drugs that may be continued in primary care following initiation and stabilisation in secondary/tertiary care  

Amber

Items requiring a shared care agreement. These items should be initiated and stabilised by secondary or tertiary care. The GP should only be asked to take over prescribing through a formal shared care agreement. Secondary care will be expected to continue prescribing until the agreement is made.  

Red

Hospital/ Trust ONLY. These are items the secondary and tertiary care are responsible for prescribing and will need to continue to prescribe for long term maintenance. These items will NOT be prescribed in primary care. But primary care should be informed the patient is receiving these items. This will include NHSE funded items requiring repatriation.  

GP - Black

Items covered by NHSE ‘Should not prescribe in primary care list’ – See CCG policy on Drugs of limited clinical value  

GP - Grey

Grey List: Items covered by NHSE ‘Should not prescribe in primary care list’ that are not to be routinely prescribed but may be suitable in a defined population – See CCG policy on Drugs of limited clinical value  

netFormulary